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Objective: To review the topic of alpha-1 antitrypsin (AAT) deﬁciency.
Method: Narrative literature review.
Results: Much work has been carried out on this condition with many questions being answered but still
further questions remain.
Discussion and conclusions: AAT deﬁciency is an autosomal co-dominantly inherited disease which affects
the lungs and liver predominantly. The clinical manifestations, prevalence, genetics, molecular patho-
physiology, screening and treatment recommendations are summarised in this review.
 2011 Published by Elsevier Ltd.Editorial
COPDcanbeadifﬁcult disease to treatwith sometimesdepressing
results. For many of the difﬁcult to treat patients continued smoking
is themain barrier to response to therapy. For about 2% of your COPD
patients the problemmay be an unrecognized co-morbidity. Alpha-1
antitrypsin deﬁciency has been considered a rare condition seldom
seen in primary care. But newer data suggests a different story.
Tenyears ago I had nevermet anyonewho I knewhad AAT deﬁciency
and I would never have considered testing for it. But now I have seen
the impact of this genetic condition and what treatment can do.
Some of this review will seem a little esoteric to many primary
care physicians but then at one time MRIs seemed overpriced and
esoteric. They may still be overpriced. In ﬁve or ten years this is one
of the things that may truly be useful in our concept of individu-
alized medicine. In the future screening may be done directly by
genetic analysis as recommended by Dr. Kelly and colleagues but
for now most of us will choose a less speciﬁc rapid screen that
when failed leads on to the more expensive genetic assessment. If
you are not doing AAT deﬁciency screening when you diagnosis
COPD please read this article. At the end of reading you should have
a better basis for your discussions regarding screening with your
COPD patients. In addition to the possible addition of AAT
replacement therapy for the COPD patient, AAT testing can provide
important information for the patient’s children and grandchildren
who would have an opportunity to use early replacement therapy.sly published article. DOI ofEducation objectives
 Learn the important role of alpha-1-antitrypsin (AAT) in lung
health.
 Learn when to consider screening for AAT deﬁciency among
people with COPD.
 Learn the potential impact of AAT replacement therapy.
1. Introduction
AAT deﬁciency is a genetic disorder that affects an approximated
3.4million individuals worldwide, when individuals with the ZZ, SZ
or SS phenotype are included.1 This condition is clinically charac-
terised by early-onset emphysema and liver disease.
AAT deﬁciency was ﬁrst documented by Laurell and Eriksson in
1963.2 They carried out a painstaking review of 1500 serum protein
electrophoresis gels in which the band for the a1 was absent. Three
out of ﬁve of these patients developed emphysema at a young age.
Since that time much work has been done on AAT deﬁciency eluci-
dating the genotypes and the phenotypes of the condition, the
clinical variation in symptoms and signs, the method of diagnosis
and of screening and the possibilities for treatment. Many questions
have been answered but with these many more questions surface.
2. Prevalence of AAT deﬁciency
AAT deﬁciency is a genetic cause of Chronic Obstructive
Pulmonary Disease (COPD). The frequency of AAT deﬁciency can
only be estimated. In one study of 965 patients with COPD who
were screened for AAT deﬁciency 1.9% were shown to have the
disease.3 Extrapolating from the National Health Information
Survey in the USAwhich estimates that 3.1 million Americans have
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emphysema is caused by AAT deﬁciency. Under-recognition of AAT
deﬁciency is a problem.When given a questionnaire addressing the
number of doctors seen for symptoms attributable to AAT deﬁ-
ciency and the onset of AAT deﬁciency-related symptoms the 300
patients studied reported a mean delay between the ﬁrst symptom
and the initial diagnosis of the disorder of 7.2 years.4 The delay in an
initial diagnosis was shown in this study to be associated with
adverse outcomes for the patients in relation to psychosocial
effects. Other consequences include slowed opportunities to offer
speciﬁc counselling and therapy. More recently this delay has
decreased slightly to a mean of 5.6 years5 demonstrating still
further room for improvement.
3. Clinical manifestations
The clinical disease associated with AAT deﬁciency can present
in a number of ways but the most frequent organs affected are the
lungs and the liver. In the lung, emphysema is the most common
manifestation. The emphysema associated with AAT deﬁciency
tends to be early in onset (i.e., in the fourth and ﬁfth decades),
panacinar in pathology and disproportionate in its effect on the
lung bases (compared to themore apical distribution in AAT replete
patients).6e8 Evidence for the association of bronchiectasis with
AAT deﬁciency is mixed. Larsson originally noted bronchiectasis in
11.3% of 246 patients with the ZZ phenotype.9 The NHLBI registry
reported bronchiectasis in only 2% of 1129 participants10 and in
a case-control study. Cuvelier and colleagues recorded no excess
frequency of AAT deﬁciency in patients with bronchiectasis
compared with those without bronchiectasis.11 A more recent
study characterising the computed tomographic phenotype of
patients with AAT deﬁciency found that clinically signiﬁcant
bronchiectasis occurred in 27% of the patients studied, greater than
previously recognised.12
After the lung the liver is the nextmost commonly affected organ
in AAT deﬁciency. In a Swedish population-based screening study of
200,000 neonates, 22 (18%) of 120 babies with the Z allele had
evidence of some liver dysfunction over follow-up to the age of 6
months, including obstructive jaundice (12%) and minor abnormal-
ities (7%).13When liver dysfunction is present the risk of progressing
to liver cirrhosis was estimated to be 50%; 25% died within the ﬁrst
decade of life and 2% developed cirrhosis later in childhood.14 Lars-
son’s study followed 246 patients with the Z mutation for up to 11
years and found liver disease in 12.2% (cirrhosis in 11.8%, neonatal
hepatitis in 0.4%, and hepatoma in 3.3%).9 Finally Eriksson’s analysis
of 38 post-mortem examinations from among 58 decedents with
expected AAT deﬁciency in Malmo, Sweden observed cirrhosis in
34% (n ¼ 14), in whom cirrhosis was suspected during life in 64%.15
The established association of Z mutation AAT deﬁciency with liver
disease has lead to the recommendation for screening all neonates,
children and adults with an unexplained liver disease for this
condition.16 Low AAT levels can lead to a diagnosis of AAT deﬁciency,
but there is no correlation betweenAAT level and risk of liverdisease.
The risk of cirrhosis in SZ patients is nowestablished. The S variant is
known to have an increased susceptibility to polymerisation,
although this is marginal comparedwith themore conformationally
unstable Z variant.17 There has been speculation that the two may
interact to produce cirrhosis, but this has never been demonstrated
experimentally.
Panniculitis is a skin condition associated with AAT deﬁciency.
This condition however is not frequent with an occurrence of about
1 in 1000 patients with AAT deﬁciency.18
Vasculitis is another of the less frequently occurring diseases
associatedwith AAT deﬁciency. An over-representation of abnormal
AAT phenotypes in people with antiproteinase 3 antibody-positive(i.e., c-ANCA-positive) vasculitis in case series has established an
association between the two conditions. Speciﬁcally, prevalence of
the Z allele among c-ANCA-positive individuals was 5.6e17.6%,
which exceeds by three-fold to nine-fold the prevalence in healthy
people.16,19 The ATS/ERS statement also recommends testing for all
adults with c-ANCA-positive vasculitis.
The precise risk of developing emphysema in people with the ZZ
phenotype is not known. Tobin et al. assessed the risk of developing
emphysema in ZZ siblings of index cases.20 They found that
emphysema was present radiographically in 90% of smokers
compared with 65% of non-smokers. A Swedish study found that in
adults homozygous for the Z allele only 29% of never smokers and
10% of ever smokers were healthy.21 The remainder had lung
disease. Findings from post-mortems reported in the same study
and of CT studies reported by Parr et al. suggest that only 14e20% of
Z homozygotes were free of COPD.22 The most common cause of
death in patients with AAT deﬁciency is respiratory failure
(accounting for 50e72% of deaths) followed by liver cirrhosis
(10e13%).23,24 The observed overall yearly mortality rate ranges
from 1.7% to 3.5%.9,23e26 Factors found to be associated with
increased mortality include older age, lower education, lower FEV1
predicted, lung transplant, and not receiving augmentation
therapy.23 In another study only age and CT assessment of propor-
tion of emphysema predicted respiratory and all-cause mortality.24
There is also an association of the Z allele of AAT with
asthma,27,28 pancreatitis29 and vascular aneurysms.30,31 Associa-
tions with some neuropsychological conditions have also been
suggested. AAT S or Z polymorphisms were shown to be present in
25% of persons with anxiety disorder and 42% of persons with
bipolar disorder compared to 10% of a control group without pre-
existing affective disorder.32 A recent study comments on how
low serum AAT in family members of individuals with autism
correlates with PiMZ genotype33 and another study suggests a link
between the Z allele and “intense creative energy”.34
4. Genetics
AAT deﬁciency is an autosomal co-dominant condition. The AAT
protein is encoded by the SERPINA1 gene, previously known as the
protease inhibitor (PI) gene, the locus for which is located on
chromosome 14q32.1.35e39 This gene for AAT has been cloned and
sequenced.40,41 The SERPINA1 gene is 12.2 kb in length with seven
exons and six introns.
The SERPINA1 gene or the PI locus is highly polymorphic with
approximately 123 single nucleotide polymorphisms (SNPs) lis-
ted.42 Differences in speed of migration of different protein variants
on gel electrophoresis have been used to identify the PI phenotype,
and these differences in migration relate to variations in protein
charge resulting from amino acid alterations (Fig. 1).43 The M allele
results in a protein with a medium rate of migration; the Z form of
the protein has the slowest rate of migration. Some individuals
inherit null alleles that result in protein levels that are not detect-
able. Individuals with a Z pattern on serum isoelectric focusing are
referred to as phenotype PIZ (encompassing both PIZZ and PIZnull
genotype variants). The S variant occurs at a frequency of 0.02e0.03
and is associated with mild reductions in serum AAT levels. The Z
variant is associated with a severe reduction in serum AAT levels.
The most common alleles are theM variants with allele frequencies
of greater than 0.95 and normal AAT levels (Table 1).
The Z allele (Glu342Lys) causes the most severe plasma deﬁciency
and is most prevalent in southern Scandinavia and the northwest
European seaboard, with gene frequencies reducing toward the south
and east of the continent.44,45 In contrast, the S allele (Glu264Val)
causes only mild plasma deﬁciency and is most common in southern
Europe and becomes less frequent as one moves northeast. The
Fig. 1. Diagnostic AAT isoelectric focussing gel. A sebla 18 AAT isoelectro focussing gel
showing migration of four different AAT isoformsdMM, MZ, MS and ZZ.
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frequencies in Europe, but the S allele is more common than in
northern Europeans. AAT deﬁciency is infrequent in the Asian, African
and the Middle Eastern populations.1
Even in patients with severe AAT deﬁciency, the development,
manifestations and progression of COPD are highly variable, which
suggest that modiﬁer genes, environmental exposures, and the
combined effect of gene and environmental factors may be relevant
to disease expression. The altered AAT protein is the product of
a single gene, but the disease phenotype is probably a result of
many genes. Genetic modiﬁers of lung disease in AAT-deﬁcient
individuals may also provide insight into COPD unrelated to AAT
deﬁciency.
The AAT protein, that the SERPINA1 gene gives rise to, is 52 kDa
and includes 394 amino acids with the active site of the enzyme
inhibitor at methionine 358. It is an antiprotease. Initially labelled
“antitrypsin” was later found to have a much higher afﬁnity for the
protease neutrophil elastase (NE). In its activity inhibiting NE, AAT
plays a pivotal role in the delicate proteaseeantiprotease balance.
The molecular defect in the Z allele is a substitution of a lysine
for a glutamic acid at position 342 due to a single base alteration in
the gene. The low protein levels result from polymerisation of the
protein within the hepatocyte endoplasmic reticulum, with
subsequent reduction in serum levels due to intracellular accu-
mulation.46 In ZZ homozygous patients the plasma AAT level is 10%
of the normal M allele and 60% in the MZ heterozygote (50% from
the M allele and 10% from the Z allele).5. Molecular pathophysiology
The AAT molecule is an acute phase glycoprotein.47 This is
synthesised and secretedmainly in the liver by hepatocytes48,49 butTable 1
PI Phenotypes and the likely clinical consequences.
Phenotype Serum concentration of AAT COPD risk
Pi-MM 20e53 mmol/L General population
Pi-MS 20e48 mmol/L Very low/general
population
Pi-SS 15e33 mmol/L Low
Pi-MZ 12e35 mmol/L Low
Pi-SZ 8e19 mmol/L Variable
Pi-ZZ 2.5e7 mmol/L High
Pi-Z-null <2.5 mmol/L Very high
Pi-null-null None Very highalso synthesised by and secreted from macrophages,50 intestinal51
and bronchial epithelial cells.52 It not only inhibits pancreatic
trypsin53 but also inhibits many other proteinases including
neutrophil elastase, cathepsin G54 and proteinase 3.55
Crystal structures have shown that AAT is composed of three
b sheets (AeC) and an exposed mobile reactive loop that presents
a peptide sequence as a pseudosubstrate for the target
proteinase.56e61 The critical amino acids within this loop are the
PIePI0 residues, methionine serine, as these act as “bait” for
neutrophil elastase.62 After docking, the enzyme cleaves the P1eP10
peptide bond of AAT and the proteinase is inactivated by a mouse-
trap action that swings it from the upper to the lower pole of the
protein in association with the insertion of the reactive loop as an
extra strand in b-sheet A.63e68 This altered product of the AAT
bound to its substrate is recognised by hepatic receptors and
cleared from circulation.69 The conformational change that
underlies the clinical disease of AAT deﬁciency interferes with the
processing of this altered protein in the hepatocyte (Fig. 2).
5.1. Molecular pathology of the liver disease
Current evidence tells us that the liver disease in Z-variant AAT
deﬁciency is caused by an accumulation of the abnormal protein in
the liver rather than a plasma deﬁciency. Strong support is provided
by the fact that null alleles, which produce no AAT, are not asso-
ciated with cirrhosis.70 In addition to this, over expression of ZAAT
in animal models results in liver damage.71,72
The presence of the Z mutation causes a conformational change
in the AAT molecule. The b sheet A opens leaving it susceptible to
interactionwith another AATmolecule to form a dimer or following
interaction with further AAT molecules to form a polymer.57,73e75
These polymers get trapped in the endoplasmic reticulum. The
experimental proof of this was in work from Lomas et al. showing
polymer formation when the puriﬁed plasma ZAAT is incubated
under physiological conditions.74 These polymers were also found
in inclusion bodies in the liver of a Z heterozygotic patient74,76 and
in hepatic cell lines expressing the Z variant.77 In work on Xenopus
oocyte cells, blocking the polymerisation with point mutations was
shown to increase secretion of mutants of AAT.78 The Z mutation
causes most of the unstable protein to form polymers.
The method by which the hepatocytes deal with the polymers
has been the source of much study. Trimming asparagine linked
oligosaccharides target ZAAT polymers into an efﬁcient non-
proteosomal disposal pathway.79e81 The proteosome pathway has
been shown to be important in some hepatic82 and extrahepatic
mammalian cell lines.83,84 Retained ZAAT stimulates an autophagic
response in the hepatocyte.85,86
The endoplasmic reticulum has a very important role in protein
folding and the handling of misfolded proteins. Speciﬁc signaling
pathways87 and effector mechanism have evolved to deal with the
temporal and developmental variation in the ER load. The upstream
signal that activates these pathways is referred to as ER stress and is
deﬁned functionally as an imbalance between the load of proteins
facing the ER and the organelle’s ability to process that load. The
cellular response to ER stress has fourmain functional components:
ER overload response (EOR), the unfolded protein response (UPR),88
a decrease in protein synthesis, and programmed cell death.89
There is a great heterogeneity of liver disease in ZAAT patients.
Experimental work shows effects with an increase in temperature,
concentration of the substrates for polymerisation73,74 and genetic
factors.90,91 Results regarding temperature vary in different studies.
One study shows no increase in intracellular ZAAT in response to
raised temperatures92 but further work in a Drosophila model of
AAT deﬁciency show a clear temperature dependence of polymer-
isation in vivo.93
Liver: ZAAT accumulation in 
hepatocyte ER leading to liver disease 
Circulation: Decreased AAT in 
circulation 
Lung: Decreased AAT in lung 
leading to unopposed protease 
activity
Fig. 2. In Z-variant AAT deﬁciency accumulation of the abnormal protein in the endoplamic reticula of hepatocytes leads to the liver disease of AATD. Decreased AAT enter
circulation and arise in the lung leading to decrease in the antiprotease activity in the lung due to a lower and a higher amount of inactive AAT. This leads to increased protease
activity and the destructive process which leads to emphysema.
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ment of the lung disease associated with AAT deﬁciency.94,95 It is in
the lung that the imbalance in the proteaseeantiprotease balance is
seen to have a major effect. In the case of Z-variant AAT deﬁciency
there is less AAT in the lung.96 The AAT that is present is 5 times less
effective than normal AAT.97e100 The residual AAT is susceptible to
inactivation by oxidation of the P1 methionine residue by free
radicals from leukocytes or direct oxidation by cigarette
smoke.54,101e103 The Z AATalso favours the formation of polymers in
the lung.104 ZAAT-deﬁcient patients have excess neutrophils in
lavage ﬂuid105 and in tissue sections of the lung106 possibly related
to the chemoattractant effect of an excess of leukotriene B4 (LTB4)
and interleukin (IL)-8107,108 and the polymers themselves.109 These
circumstances of unopposed proteolytic enzyme activity and an
increase in inﬂammatory conditions cause the trademark emphy-
sema of this disease.6. Screening
Recommendations for screening for AAT deﬁciency have been
clariﬁed with publication of the American Thoracic Society/Euro-
pean Respiratory Society statement on diagnosis and management
of the condition.16 The four main beneﬁts of early detection of AAT
deﬁciency are 1. smoking prevention/cessation 2. minimizing the
hazards of occupational respiratory pollutants 3. allowing oppor-
tunities to receive augmentation therapy and 4. the potential for
family planning and guided genetic counselling/testing.110 Symp-
tomatic individuals may require life-long therapy, and early
detection may reduce the clinical and economic burdens of
progressive lung deterioration.111
Smoking cessation advice has proven to be effective in patients
with AAT deﬁciency. Follow-up of the original patients from the
1970s AAT deﬁciency screening program in Sweden who are now
30 years of age has shown that smoking is less common in them
than in control subjects.112 Further studies showed that following
screening the subsequent provision of information and advice
prevented the majority of affected adolescents from smoking.113,114
It is perceived that knowledge of AATD diagnosis should aid
affected individuals in their occupational choices, allowing them to
avoid exposure to environmental agents (e.g. avoiding careers in
steel-manufacturing).Augmentation therapy is available and will be discussed inmore
detail in the next section. Early diagnosis with screening programs
allows this to be instigated while lung function is preserved.
The impact of diagnosis through screening has multiple impli-
cations for the individual. There is a psychological impact of the
diagnosis which can be positive for patients satisﬁed to have found
a reason for their symptoms but may be negative with concerns for
the future. The ethics of screening family members raises a chal-
lenge especially in respect to minors who have the decision made
for them. The consequences of a conﬁrmed diagnosis of AATD
include possible discrimination for example by employers and
insurers.
Screening with genotyping is recommended. AAT levels may be
less expensive but establishing the genotype gives more informa-
tion about the likelihood of developing clinical consequences of the
disease.
7. Treatment of AAT deﬁciency
As AAT deﬁciency results in COPD the medical therapy for COPD
also applies to AAT deﬁciency. These have been outlined in previous
published guidelines of the ATS, BTS and the GOLD guidelines.115e117
Most patients with AAT deﬁciency and obstructive lung disease ﬁnd
symptomatic beneﬁt from bronchodilators even though objective
bronchodilator responsiveness may be lacking. Those with proven
bronchial hyperreactivity may be given an inhaled steroid with the
presumption that a decrease in bronchial inﬂammation may reduce
the loss in FEV1 over time. A study has suggested beneﬁt of inhaled
steroids in some patients with AAT deﬁciency-related lung disease,
although it is not clear which patients beneﬁt.118 Antibiotics are rec-
ommended for treatment of exacerbations triggered by bacterial
infections. Portable oxygen is recommended for thosewho desaturate
with exercise but otherwise long-term oxygen therapy is only rec-
ommended for those with severe hypoxaemia. This should be
prescribed in concordance with the ATS and ERS criteria.115,116 Oral
steroids canbecautiouslyconsidered inpatientswith a clearasthmatic
component to their disease and long-term use should be avoided. Co-
morbidities that accompany COPD outside the setting of AAT deﬁ-
ciency should always be borne in mind. These include depression,
anxiety and malnutrition. Pulmonary rehabilitation can offer beneﬁt;
improving endurance, reducing dyspnoea and reducing number of
hospitalisations.119
E. Kelly et al. / Respiratory Medicine CME 4 (2011) 1e8 5Treatment speciﬁc to AAT deﬁciency is centred on AAT augmen-
tation therapy. There are four potential treatment options (1) intra-
venous human plasma-derived augmentation therapy, (2)
augmentation therapy by inhalation, (3) recombinant AAT
augmentation therapy, and (4) synthetic elastase inhibition.
7.1. Intravenous human plasma-derived augmentation therapy
Since the early 1980s intravenous administration of puriﬁed
human AATconcentratewas shown to increase lung levels of AAT in
AAT-deﬁcient patients.96,120 Patients receiving once weekly IV
doses increased the antineutrophil elastase capacity in lung
epithelium lining ﬂuid by 60e70%. A puriﬁed preparation was
manufactured and shown to be biologically active121e123 and this
lead to the US Food and Drug Administration approval in the United
States in 1988. Randomised placebo-controlled trials evaluating the
effect of IV AAT replacement therapy in attenuating the develop-
ment of emphysema are lacking with only one published.124
Recommendations on the use of augmentation therapy are based
on the ATS/ERS guidelines.16
Decline in FEV1 has been shown to be lower in patients treated
with IV augmentation therapy compared with untreated
patients.125,126 In comparing the different degrees of functional
impairment, a signiﬁcant effect of the treatment was demonstrated
only in the group of patients with an initial FEV1 of 31e65% pre-
dicted. This non-randomised study showed that weekly infusion of
human AAT in patients withmoderately reduced lung functionmay
slow the annual decline in FEV1. In a similar study from the NHLBI
Registry the mortality rate was lower in those receiving augmen-
tation therapy as compared with those not receiving therapy and
mean FEV1 decline was only slowed in the subgroup of patients
with moderate emphysema. The only randomised trial was small
with only 58 patients. The number of patients limited the only
signiﬁcant ﬁnding to being an attenuation in the loss of lung
density in the treated group.124
7.2. Augmentation therapy by inhalation
Aerosol application of AAT in patients with AAT deﬁciency
increases AAT concentration and anti-elastase activity in the lower
respiratory tract in a dose-dependent fashion.127 Preliminary data
suggest that one or twice daily administration of aerosolized AAT
may produce sustained anti-elastase protection of the lungs.
7.3. Recombinant AAT augmentation therapy and synthetic
elastase inhibition
A number of recombinant forms of AAT have been developed as
well as recombinant secretory leukoprotease inhibitor128 and
several synthetic low molecular weight elastase inhibitors are
being evaluated but their clinical efﬁcacy and safety have not been
reported.
In summary the available studies indicate a lowered overall
mortality and a slower rate of FEV1 decline in augmentation
therapy recipients with FEV1 values of 35e65% of predicted.
Lung transplantation may be recommended for some patients
with end-stage lung disease. Due to limitations on available donor
lungs single lung transplant is more common despite the fact that
outcome has been shown to be better in patient who receive double
lung transplant. Approximately 12% of all lung transplant opera-
tions for emphysema are due to AAT deﬁciency.129 Five year
survival rates following lung transplant is approximately 50% with
bronchiolitis obliterans being the major cause of death post-
transplant.1307.4. Lung volume reduction surgery
Lung volume reduction surgery (LVRS) improves exercise
capacity and relieves dyspnoea in patients with usual emphysema
but the story is less clear in AAT deﬁciency. One study showed
a beneﬁt to bilateral LVRS in AAT-deﬁcient patients with emphy-
sema but functional measurements (except 6 min walk test)
returned to baseline at 6e12 months.131 LVRS was not recom-
mended in the ATS/ERS guidelines for management of AAT deﬁ-
ciency in their 2003 statement.
8. Future research
A large volume of research continues in the ﬁeld of AAT deﬁ-
ciency. Three examples are in the ﬁeld of candidate modiﬁer genes,
anti-inﬂammatory proteins and potential synthetic antiproteases.
Although the gene responsible for the conformational change
in AAT has been identiﬁed variations in the presentation
of patients strongly suggests the role for candidate modiﬁer
genes. An example of a potential modiﬁer is Selenoprotein S/
SEPS1. This selenoprotein has been shown to decrease mani-
festations of ER stress in an in vitro model of Z-variant AAT
deﬁciency.132
Other anti-inﬂammatory therapies will continue to be
investigated in this disease. Recent work showed that bron-
choalveolar lavage (BAL) ﬂuid from patients with AAT deﬁciency
containing free neutrophil elastase had increased cathepsin B
and matrix metalloproteinase-2 (MMP2) activities compared
with BAL ﬂuid from healthy volunteers. AAT augmentation
therapy to AAT-deﬁcient individuals reduced cathepsin B and
MMP-2 activity in BAL ﬂuid in vivo. Furthermore, AAT-deﬁcient
patients had higher levels of secretory leukocyte peptidase
inhibitor (SLPI) and lactoferrin after AAT augmentation therapy
suggesting a novel role for AAT inhibition of NE-induced upre-
gulation of MMP and cathepsin expression both in vitro and in
vivo.133
Conclusion
AAT deﬁciency is an under diagnosed disease causing much
morbidity and mortality in those affected. Much has been eluci-
dated about the genetics and the molecular pathophysiology and
potential therapies of this condition. Further research continues to
investigate the varying presentations between different patients
with AAT deﬁciency and the full effect of AAT and the body’s
response to it.
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1. AAT deﬁciency is recognized and treated promptly.
a. True
b. False
2. Knowing the type of AAT deﬁciency gene mutation patterns is
of no value.
a. True
b. False
3. The mechanism of disease progression is the same in the liver
and the lung for people with AAT deﬁciency.
a. True
b. False
4. The methods of possible AAT therapy include:
a. Intravenous plasma derived therapy
b. Inhalation augmentation therapy
c. Recombinant AAT augmentation therapy
d. Synthetic elastase inhibition therapy
e. All of the aboveReferences
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